Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      China Jo-Jo Drugstores Reports Second Quarter 2021 Financial Results


      News provided by

      China Jo-Jo Drugstores, Inc.

      Nov 13, 2020, 09:00 ET

      Share this article

      Share this article


      HANGZHOU, China, Nov. 13, 2020 /PRNewswire/ -- China Jo-Jo Drugstores, Inc. (NASDAQ: CJJD) ("Jo-Jo Drugstores" or the "Company"), a leading online and offline retailer, wholesale distributor of pharmaceutical and other healthcare products and healthcare provider in China, today announced its financial results for the second fiscal quarter ended September 30, 2020.

      Mr. Lei Liu, Chairman and CEO of Jo-Jo Drugstores, commented, "We are pleased with our second quarter performance as we delivered another quarter of strong results. Our revenue and gross profit recorded $30.84 million and $7.01 million for the second fiscal quarter of 2021, up 8.8% and 4.8% compared to same period of fiscal year 2020. Revenue year-over-year from online pharmacy increased by 127.4%. We have always been deeply committed to our communities, and we have taken necessary measures to protect the safety and health of our customers and employees during the global COVID-19 pandemic while making solid progress on our transformation strategy of 'Medical Linkage & Technology Empowerment'. The environment surrounding COVID-19 is accelerating our transformation, giving us new opportunities to demonstrate our capabilities and gain retail market share in China. We are building a strong foundation for sustainable growth and setting the platform to engage with consumers, and we are remaining focused on creating value for all our stakeholders."  

      Second Quarter of Fiscal 2021 Financial Highlights



      For the Three Months Ended September 30,

      ($ millions, except per share data)


      2020


      2019


      % Change

      Revenue


      30.84


      28.35


      8.8%

            Retail drugstores


      17.93


      18.00


      -0.4%

            Online pharmacy


      5.35


      2.35


      127.4%

            Wholesale


      7.56


      8.00


      -5.5%

      Gross profit


      7.01


      6.69


      4.8%

      Gross margin


      22.7%


      23.6%


      -0.9 pp*

      Loss from operations


      (1.52)


      (1.62)


      5.7%

      Net loss


      (1.53)


      (1.35)


      -13.4%

      Loss per share


      (0.04)


      (0.04)


      -%


      *Notes: pp represents percentage points

      • Revenue increased by 8.8% to $30.84 million for the three months ended September 30, 2020 from $28.35 million for the same period of last year.
      • Gross profit increased by 4.8% to $7.01 million for the three months ended September 30, 2020 from $6.69 million for the same period of last year.
      • Gross margin decreased slightly by 0.9 percentage points to 22.7% for the three months ended September 20, 2020 from 23.6% for the same period of last year.
      • Net loss was $1.53 million, or $0.04 per basic and diluted share, for the three months ended September 30, 2020, compared to net loss of $1.35 million, or $0.04 per basic and diluted share, for the same period of last year.

      Second Quarter of Fiscal 2021 Financial Results

      Revenue

      Revenue for the three months ended September 30, 2020 increased by $2.49 million, or 8.8%, to $30.84 million from $28.35 million for the same period of last year. The increase in revenue was primarily due to the growth in online pharmacy business.



      For the Three Months Ended September 30,



      2020


      2019

      ($ millions)


      Revenue


      Cost of
      Goods


      Gross
      Margin


      Revenue


      Cost of
      Goods


      Gross
      Margin

      Retail drugstores


      17.93


      12.33


      31.3%


      18.00


      12.47


      30.7%

      Online pharmacy


      5.35


      4.74


      11.3%


      2.35


      2.03


      13.6%

      Wholesale


      7.56


      6.76


      10.7%


      8.00


      7.16


      10.6%

      Total


      30.84


      23.83


      22.7%


      28.35


      21.66


      23.6%

      Revenue from the retail drugstores business decreased slightly by $0.07 million, or 0.4%, to $17.93 million for the three months ended September 30, 2020 from $18.00 million for the same period of last year. The slight decrease was primarily due to the Company's strategical abandoning of the sales of certain low-profit margin products reimbursed by National Healthcare Security Administration ("NHSA" hereafter) due to its overall budget, elimination of a variety of drugs off the list of drugs reimbursed by the local NHSA since September 1, 2020, and the negative effect on the overall economy from COVID-19.

      Revenue from the online pharmacy business increased by $3.00 million, or 127.4%, to $5.35 million for the three months ended September 30, 2020 from $2.35 million for the same period of last year. The increase was primarily caused by an increase in sales of prescription drugs via e-commerce platforms such as Tmall. Prescription drugs used to be prohibited from sales online due to safety concern. However, because the nation has lifted the ban order, online prescription drug sales become popular. As a result, the sale of prescription drugs was $1.76 million in the three months ended September 30, 2020 as compared to none in the three month ended September 30, 2019. Additionally, the Company maintained a membership care program targeted at customers with chronic disease. The Company has closely interacted with its members via WeChat by providing healthcare knowledge and reminding them to refill medicine. By implementing a personalized customer care program, the Company was able to promote its sales.

      Revenue from the wholesale business decreased by $0.44 million, or 5.5%, to $7.56 million for the three months ended September 30, 2020 from $8.00 million for the same period of last year. The decrease was primarily due to the fact that a key salesperson was sick, which slowed certain business with customers.

      Gross profit and gross margin

      Total cost of goods sold increased by $2.17 million, or 10.0%, to $23.83 million for the three months ended September 30, 2020 from $21.66 million for the same period of last year. Gross profit increased by $0.32 million, or 4.8%, to $7.01 million for three months ended September 30, 2020 from $6.69 million for the same period of last year. Overall gross margin decreased slightly by 0.9 percentage points to 22.7% for the three months ended September 30, 2020, from 23.6% for the same period of last year.

      Gross margins for retail drugstores, online pharmacy and wholesale were 31.3%, 11.3%, and 10.7%, respectively, for the three months ended September 30, 2020, compared to gross margins for retail drugstores, online pharmacy and wholesale of 30.7%, 13.6%, and 10.6%, respectively, for the same period of last year.

      Loss from operations

      Selling and marketing expenses decreased by $0.01 million, or 0.2%, to $6.48 million for the three months ended September 30, 2020 from $6.49 million for the same period of last year. The decrease in selling and marketing expenses was primarily due to the control of in-store advertising expense, offset by the increase in fee charged by various platforms as a result of sale increase in the Company's online pharmacy.

      General and administrative expenses increased by $0.24 million, or 13.0%, to $2.06 million for the three months ended September 30, 2020 from $1.82 million for the same period of last year. In the three months ended September 30, 2020, the Company reversed bad debt allowance of $304,397 as compared to an increase in bad debt allowance of $9,018 in the same period of last year. Excluding such effect, the general and administrative expenses increased by $551,039 period over period, which reflects the increase in staff and administration expense.

      Loss from operations was $1.52 million for the three months ended September 30, 2020, compared to $1.62 million for the same period of last year. Operating margin was (4.9)% and (5.7)% for the three months ended September 30, 2020 and 2019 respectively.

      Net loss

      Net loss was $1.53 million, or $0.04 per basic and diluted share for the three months ended September 30, 2020, compared to net loss of $1.35 million, or $0.04 per basic and diluted share for the same period of last year.

      Six Months Ended September 30, 2020 Financial Highlights



      For the Six Months Ended September 30,

      ($ millions, except per share data)


      2020


      2019


      % Change

      Revenue


      61.90


      53.63


      15.4%

            Retail drugstores


      36.74


      34.74


      5.8%

            Online pharmacy


      10.26


      4.79


      114.0%

            Wholesale


      14.90


      14.10


      5.6%

      Gross profit


      14.99


      12.75


      17.5%

      Gross margin


      24.2%


      23.8%


      0.4 pp*

      Loss from operations


      (1.94)


      (4.38)


      55.7%

      Net loss


      (1.92)


      (3.73)


      48.6%

      Loss per share


      (0.05)


      (0.10)


      50.0%


      *Notes: pp represents percentage points

      • Revenue increased by 15.4% to $61.90 million for the six months ended September 30, 2020 from $53.63 million for the same period of last year.
      • Gross profit increased by 17.5% to $14.99 million for the six months ended September 30, 2020 from $12.75 million for the same period of last year.
      • Gross margin increased by 0.4 percentage points to 24.2% for the six months ended September 20, 2020 from 23.8% for the same period of last year.
      • Net loss was $1.92 million, or $0.05 per basic and diluted share, for the six months ended September 30, 2020, compared to net loss of $3.73 million, or $0.10 per basic and diluted share, for the same period of last year.

      Six Months Ended September 30, 2020 Financial Results

      Revenue

      Revenue for the six months ended September 30, 2020 increased by $8.26 million, or 15.4%, to $61.90 million from $53.63 million for the same period of last year. The increase in revenue was primarily due to the increase in retail drugstores, online pharmacy and wholesale business.



      For the Six Months Ended September 30,



      2020


      2019

      ($ millions)


      Revenue


      Cost of
      Goods


      Gross
      Margin


      Revenue


      Cost of
      Goods


      Gross
      Margin

      Retail drugstores


      36.74


      24.73


      32.7%


      34.74


      24.15


      30.5%

      Online pharmacy


      10.26


      8.97


      12.5%


      4.79


      4.13


      13.9%

      Wholesale


      14.90


      13.20


      11.4%


      14.10


      12.60


      10.7%

      Total


      61.90


      46.90


      24.2%


      53.63


      40.88


      23.8%

      Revenue from the retail drugstores business increased by $2.00 million, or 5.8%, to $36.74 million for the six months ended September 30, 2020 from $34.74 million for the same period of last year. The increase was primarily attributable to consumer-facing benefits such as emphasis on onsite medical care, chronic disease management services, incremental Direct-to-Patient ("DTP") business caused by continuous hospital medical reform, partially offset by the decline in sale reimbursed by NHSA in the second quarter of fiscal 2021, and maturing of stores opened a year ago.

      Revenue from the online pharmacy business increased by $5.47 million, or 114.0%, to $10.26 million for the six months ended September 30, 2020 from $4.79 million for the same period of last year. The increase was primarily caused by an increase in sales of prescription drugs via e-commerce platforms such as Tmall. Due to the same reason discussed above, the sale of prescription drugs was $3.63 million in the six months ended September 30, 2020 as compared to none in the six month ended September 30, 2019. Additionally, the Company maintained a membership care program targeted at customers with chronic disease. The Company has closely interacted with its members via WeChat by providing healthcare knowledge and reminding them to refill medicine. By implementing a personalized customer care program, the Company was able to promote its sales.

      Revenue from the wholesale business increased by $0.80 million, or 5.6%, to $14.90 million for the six months ended September 30, 2020 from $14.10 million for the same period of last year. The increase was primarily a result of the Company's ability to resell certain products, which the Company sold in large quantities at its retail stores, to other vendors at competitive prices.

      Gross profit and gross margin

      Total cost of goods sold increased by $6.02 million, or 14.7%, to $46.90 million for the six months ended September 30, 2020 from $40.88 million for the same period of last year. Gross profit increased by $2.24 million, or 17.5%, to $14.99 million for the six months ended September 30, 2020 from $12.75 million for the same period of last year. Overall gross margin increased by 0.4 percentage points to 24.2% for the six months ended September 30, 2020, from 23.8% for the same period of last year.

      Gross margins for retail drugstores, online pharmacy and wholesale were 32.7%, 12.5%, and 11.4%, respectively, for the six months ended September 30, 2020. This compared to gross margins for retail drugstores, online pharmacy and wholesale of 30.5%, 13.9%, and 10.7%, respectively, for the same period of last year.

      Loss from operations

      Selling and marketing expenses increased by $0.30 million, or 2.4%, to $12.75 million for the six months ended September 30, 2020 from $12.45 million for the same period of last year. The increase in selling and marketing expenses was primarily due to increase in fee charged by various platforms as a result of sale increase in the Company's online pharmacy.

      General and administrative expenses decreased by $0.50 million, or 10.6%, to $4.18 million for the six months ended September 30, 2020 from $4.68 million for the same period of last year. In the six months ended September 30, 2020, the Company reversed bad debt allowance of $286,076 as compared to an increase in bad debt allowance of $767,249 in the same period of last year. Excluding such an effect, the general and administrative expenses increased by $559,503 period over period, which reflects the increases in staff and administration expense as the Company's online business grew. 

      Loss from operations was $1.94 million for the six months ended September 30, 2020, compared to $4.38 million for the same period of last year. Operating margin was (3.1)% and (8.2)% for the six months ended September 30, 2020 and 2019 respectively .

      Net loss

      Net loss was $1.92 million, or $0.05 per basic and diluted share for the six months ended September 30, 2020, compared to net loss of $3.73 million, or $0.10 per basic and diluted share for the same period of last year.

      Financial Condition

      As of September 30, 2020, the Company had cash of $21.65 million, compared to $16.18 million as of March 31, 2020. Net cash used in operating activities was $0.35 million for the six months ended September 30, 2020, compared to net cash provided by operating activities of $0.97 million for the same period of last year. Net cash used in investing activities was $1.76 million for the six months ended September 30, 2020, compared to $1.45 million for the same period of last year. Net cash provided by financing activities was $4.55 million for the six months ended September 30, 2020, compared to $6.38 million for the same period of last year.

      About China Jo-Jo Drugstores, Inc.

      China Jo-Jo Drugstores, Inc. ("Jo-Jo Drugstores" or the "Company"), is a leading online and offline retailer and wholesale distributor of pharmaceutical and other healthcare products and a provider of healthcare services in China. Jo-Jo Drugstores currently operates an online pharmacy and retail drugstores with licensed doctors on site for consultation, examination and treatment of common ailments at scheduled hours. It is also a wholesale distributor of products similar to those carried in its pharmacies. For more information about the Company, please visit http://jiuzhou360.com. The Company routinely posts important information on its website.

      Forward-Looking Statements

      This press release contains information about the Company's view of its future expectations, plans and prospects that constitute forward-looking statements. Actual results may differ materially from historical results or those indicated by these forward-looking statements as a result of a variety of factors including, but not limited to, risks and uncertainties associated with its ability to raise additional funding, its ability to maintain and grow its business, variability of operating results, its ability to maintain and enhance its brand, its development and introduction of new products and services, the successful integration of acquired companies, technologies and assets into its portfolio of products and services, marketing and other business development initiatives, competition in the industry, general government regulation, economic conditions, dependence on key personnel, the ability to attract, hire and retain personnel who possess the technical skills and experience necessary to meet the requirements of its clients, and its ability to protect its intellectual property. The Company's encourages you to review other factors that may affect its future results in the Company's annual reports and in its other filings with the Securities and Exchange Commission.

      For more information, please contact:

      Company Contact: 

      Frank Zhao
      Chief Financial Officer
      +86-571-88077108
      [email protected]

      Steve Liu
      Investor Relations Director
      [email protected]

      Investor Relations Contact:

      Tina Xiao
      Ascent Investor Relations LLC
      +1-917-609-0333
      [email protected]

      CHINA JO-JO DRUGSTORES, INC. AND SUBSIDIARIES

      CONDENSED CONSOLIDATED BALANCE SHEETS

      (UNAUDITED)




      September 30,



      March 31,




      2020



      2020


      ASSETS







      CURRENT ASSETS







      Cash and cash equivalents


      $

      21,646,487



      $

      16,176,318


      Restricted cash



      13,722,479




      14,806,288


      Financial assets available for sale



      163,818




      157,159


      Notes receivable



      73,494




      57,005


      Trade accounts receivable



      9,992,142




      9,770,656


      Inventories



      13,227,559




      12,247,004


      Other receivables, net



      5,225,418




      5,069,442


      Advances to suppliers



      1,929,273




      1,174,800


      Other current assets



      1,833,208




      1,528,540


      Total current assets



      67,813,878




      60,987,212











      PROPERTY AND EQUIPMENT, net



      6,768,478




      7,633,740











      OTHER ASSETS









      Long-term investment



      4,115,839




      2,544,451


      Farmland assets



      789,638




      742,347


      Long term deposits



      1,533,640




      1,456,384


      Other noncurrent assets



      1,077,100




      1,046,763


      Operating lease right-of-use assets



      19,946,821




      21,711,376


      Intangible assets, net



      3,440,046




      3,393,960


      Total other assets



      30,903,084




      30,895,281











      Total assets


      $

      105,485,440



      $

      99,516,233











      LIABILITIES AND STOCKHOLDERS' EQUITY









      CURRENT LIABILITIES









      Short-term bank loan


      $

      2,204,820




      1,410,130


      Accounts payable, trade



      24,904,087




      21,559,494


      Notes payable



      23,327,972




      26,605,971


      Other payables



      1,888,563




      2,522,330


      Other payables - related parties



      574,103




      490,218


      Customer deposits



      1,262,520




      708,140


      Taxes payable



      245,203




      119,247


      Accrued liabilities



      653,409




      753,612


      Long-term loan payable-current portion



      2,375,729




      2,287,742


      Current portion of operating lease liabilities



      1,056,181




      981,090


      Total current liabilities



      58,492,587




      57,437,974











      Long-term loan payable



      3,089,373




      4,115,958


      Long-term operating lease liabilities



      16,500,499




      19,049,575


      Employee Deposits



      14,699




      70,507


      Purchase option and warrants liability



      36,306




      64,090


      Total liabilities



      78,133,464




      80,738,104











      COMMITMENTS AND CONTINGENCIES


















      STOCKHOLDERS' EQUITY









      Common stock; $0.001 par value; 250,000,000 shares authorized; 37,961,790 and
           32,936,786 shares issued and outstanding as of September 30, 2020 and March
           31, 2020, respectively



      37,962




      32,937


      Preferred stock; $0.001 par value; 10,000,000 shares authorized; nil issued and
           outstanding as of September 30 and March 31, 2020, respectively



      -




      -


      Additional paid-in capital



      63,568,876




      54,209,301


      Statutory reserves



      1,309,109




      1,309,109


      Accumulated deficit



      (38,126,065)




      (36,400,837)


      Accumulated other comprehensive income



      2,565,454




      1,440,424


      Total stockholders' equity



      29,355,336




      20,590,934


      Noncontrolling interests



      (2,003,360)




      (1,812,805)


      Total equity



      27,351,976




      18,778,129


      Total liabilities and stockholders' equity


      $

      105,485,440



      $

      99,516,233


      CHINA JO-JO DRUGSTORES, INC. AND SUBSIDIARIES

      CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

      (UNAUDITED)




      For the three months ended
      September 30,



      For the six months ended
      September 30,




      2020



      2019



      2020



      2019















      REVENUES, NET


      $

      30,842,545



      $

      28,353,779



      $

      61,896,857



      $

      53,634,563



















      COST OF GOODS SOLD



      23,829,793




      21,660,415




      46,903,886




      40,879,761



















      GROSS PROFIT



      7,012,752




      6,693,364




      14,992,971




      12,754,802



















      SELLING EXPENSES



      6,475,512




      6,485,848




      12,747,919




      12,454,399


      GENERAL AND ADMINISTRATIVE EXPENSES



      2,061,559




      1,823,935




      4,181,725




      4,675,547


      TOTAL OPERATING EXPENSES



      8,537,071




      8,309,783




      16,929,644




      17,129,946



















      LOSS FROM OPERATIONS



      (1,524,319)




      (1,616,419)




      (1,936,673)




      (4,375,144)



















      OTHER INCOME (EXPENSE):

















      INTEREST INCOME



      187,667




      340,514




      351,255




      388,387


      INTEREST EXPENSE



      (117,692)




      -




      (245,079)




      -


      OTHER



      (124,496)




      (72,225)




      (74,475)




      (134,710)


      CHANGE IN FAIR VALUE OF DERIVATIVE
      LIABILITIES



      32,674




      6,865




      27,784




      410,420



















      LOSS BEFORE INCOME TAXES



      (1,546,166)




      (1,341,265)




      (1,877,188)




      (3,711,047)



















      PROVISION FOR INCOME TAXES



      (18,975)




      5,702




      38,595




      14,090



















      NET LOSS



      (1,527,191)




      (1,346,967)




      (1,915,783)




      (3,725,137)



















      LESS: NET LOSS ATTRIBUTABLE TO
         NONCONTROLLING INTEREST



      (33,472)




      (122,004)




      (190,555)




      (365,223)



















      NET LOSS ATTRIBUTABLE TO CHINA JO-JO
         DRUGSTORES, INC.



      (1,493,719)




      (1,224,963)




      (1,725,228)




      (3,359,914)



















      Foreign currency translation adjustments



      1,031,461




      (536,335)




      1,125,030




      (941,573)



















      COMPREHENSIVE LOSS


      $

      (495,730)



      $

      (1,883,302)



      $

      (790,753)



      $

      (4,666,710)



















      WEIGHTED AVERAGE NUMBER OF SHARES:

















      Basic



      37,961,790




      32,936,786




      36,232,144




      32,696,348


      Diluted



      37,961,790




      32,936,786




      36,232,144




      32,696,348



















      EARNINGS PER SHARES:

















      Basic


      $

      (0.04)



      $

      (0.04)



      $

      (0.05)



      $

      (0.10)


      Diluted


      $

      (0.04)



      $

      (0.04)



      $

      (0.05)



      $

      (0.10)


      CHINA JO-JO DRUGSTORES, INC. AND SUBSIDIARIES

      CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS

      (UNAUDITED)




      For the six months ended
      September 30,




      2020



      2019


      CASH FLOWS FROM OPERATING ACTIVITIES:







      Net loss


      $

      (1,915,783)



      $

      (3,725,137)


      Adjustments to reconcile net income to net cash provided by operating activities:









      Bad debt direct write-off and provision



      (286,076)




      767,250


      Depreciation and amortization



      1,258,156




      1,051,907


      Stock based compensation



      -




      34,560


      Change in fair value of purchase option derivative liability



      (27,784)




      (410,420)


      Changes in operating assets and liabilities:









      Accounts receivable, trade



      41,724




      555,289


      Notes receivable



      (13,675)




      92,655


      Inventories and biological assets



      (448,573)




      975,170


      Other receivables



      279,650




      (206,247)


      Advances to suppliers



      (531,255)




      (106,790)


      Other current assets



      (853,289)




      (1,031,185)


      Long term deposit



      (15,106)




      682,504


      Other noncurrent assets



      13,619




      13,791


      Accounts payable, trade



      2,362,338




      1,938,015


      Other payables and accrued liabilities



      (845,411)




      (568,457)


      Customer deposits



      509,549




      744,912


      Taxes payable



      123,082




      165,692











      Net cash used in/provided by operating activities



      (348,834)




      973,509











      CASH FLOWS FROM INVESTING ACTIVITIES:









      Disposal of financial assets available for sale



      -




      14,457


      Acquisition of equipment



      (33,968)




      (374,992)


      Purchases of intangible assets



      (55,038)




      (462,266)


      Investment in a joint venture



      (1,422,193)




      -


      Additions to leasehold improvements



      (246,846)




      (622,464)


      Net cash used in investing activities



      (1,758,045)




      (1,445,265)











      CASH FLOWS FROM FINANCING ACTIVITIES:









      Proceeds from short-term bank loan



      714,160




      682,692


      Repayment of  third parties' loan



      (1,175,725)




      -


      Proceeds from notes payable



      22,668,388




      21,745,277


      Repayment of notes payable



      (26,949,176)




      (24,862,363)


      Decrease in Employee Deposits



      (57,133)




      -


      Exercise of warrants



      77,500




      -


      Proceeds from equity financing



      9,205,173




      9,273,077


      Repayment of other payables-related parties



      68,994




      (458,002)


      Net cash provided by financing activities



      4,552,181




      6,380,681











      EFFECT OF EXCHANGE RATE ON CASH



      1,941,058




      (1,368,958)











      INCREASE IN CASH AND CASH EQUIVALENTS AND RESTRICTED CASH



      4,386,360




      4,539,967











      CASH AND CASH EQUIVALENTS AND RESTRICTED CASH, beginning of period



      30,982,606




      24,745,202











      CASH AND CASH EQUIVALENTS AND RESTRICTED CASH, end of period


      $

      35,368,966



      $

      29,285,169











      SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:









          Cash paid for interest



      247,371




      -


      Cash paid for income taxes


      $

      3,457



      $

      28,777


      SOURCE China Jo-Jo Drugstores, Inc.

      Modal title

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.